Published on : Aug 16, 2017
Albany, New York, August 16, 2017: A latest report titled “Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis,” speaks about the current scenario of the global market of adult vaccines. It provides decisive information about the vaccine administration and overall market share in the aforementioned forecast period.
The adult vaccines market is expected to reach an overall valuation of US$20 bn by the end of 2022. Almost all the nations around the world have implemented National Immunization Program to prevent rise of possible epidemics created by vaccine-preventable diseases. This widespread use of adult vaccines have led diseases such as polio and diphtheria to become less effective across the globe. Programs such as the GAVI Alliance, Global Immunization Vision and Strategy (GIVS), and WHO’s Global Vaccine Action Plan are trying their best to cut down the impact of the vaccine-preventable diseases. These activities are estimate to drive the global adult vaccine market during the forecast period
The report studies the adult vaccine market from three viewpoints viz. people immunized vaccines, doses of vaccines administered, and global adult vaccines. The report also studies various vaccines in the market for diseases such as influenza, zoster, MMRV (Measles, Mumps, Rubella, and Varicella), cervical cancer, meningitis, pneumonia, hepatitis, DTap (Diphtheria, Tetanus, and Pertussis) and vaccines for travelers among others.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=1237587
The adult vaccine market is likely to be dominated by influenza vaccine in 2017. However, it is expected to fall behind the pneumococcal vaccine in the near future. This is mainly because patients suffering from pneumonia have grown almost three times over the past 15 years. Other than the pneumococcal and influenza vaccines, vaccines for cervical cancer (HPV), travel, and hepatitis have also significantly contributed to the overall market share in the global adult vaccines market. Moreover, considerable R&D activities in immunization of zoster, meningococcal, DTap, MMRV, hepatitis, and cervical cancer (HPV) are also expected to boost the growth of the adult vaccines market.
Influenza disease holds the maximum share in terms of immunization as the vaccination for influenza is advised to administer annually in almost all nations across the globe. The report also estimates that there will be significant rise in the number of people opting for zoster, cervical cancer (HPV), meningococcal, DTap, and MMRV vaccines in the mentioned forecast period.
In terms of vaccine doses administration, influenza vaccines will lead the pack. This is down to the fact that influenza strains alter every year and become mandatory for people to get themselves vaccinated against the disease. Following influenza, pneumococcal, cervical cancer (HPV), and hepatitis vaccines have shown considerable growth in the number of administered doses.
The research study on the global adult vaccines market has mentioned some prominent players such as Merck & Co., Pfizer Inc., Sanofi Pasteur, and GlaxoSmithKline Plc. among others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com